MedTrace Logo

Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation

NCT00165074 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2007-11-22

No results posted yet for this study

Summary

The purpose of the study is to determine whether additional surfactant(Infasurf) doses at 7 to 10 days of life time will improve lung function in premature infants, allowing a decrease in required oxygen concentration and ventilator settings.

Conditions

  • Respiratory Distress Syndrome

Interventions

DRUG

Infasurf (drug)

Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses

Sponsors & Collaborators

Principal Investigators

  • Michael Posencheg, MD · University of Pennsylvania/Children's Hospital of Philadelphia

  • Roberta A Ballard, MD · University of California, San Francisco Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Days
Max Age
10 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2007-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165074 on ClinicalTrials.gov